Search clinical trials for: Smoldering Multiple Myeloma

Total 12996 results

First Affiliated Hospital of Zhejiang University
First Affiliated Hospital of Wenzhou Medical University; The Affiliated Hospital... and other collaborators

Recruiting

Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not

Multiple Myeloma | Minimal Residual Disease

China
Nanjing IASO Biotechnology Co., Ltd.

Recruiting

A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03) (FUMANBA-03)

Multiple Myeloma

China
National Cancer Institute (NCI)

Not yet recruiting

Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Hard-to-Treat Multiple Myeloma

Multiple Myeloma
Stanford University
Janssen, LP

Not yet recruiting

Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma

Multiple Myeloma | Post Stem Cell Transplant

United States
Assiut University

Not yet recruiting

Clinical Outcomes and Prognostic Factors in Multiple Myeloma Patients

Multiple Myeloma
Durham VA Medical Center
Duke University

Not yet recruiting

Telehealth-based Symptom Management for Veterans Treated With Selinexor (Selinexor)

Multiple Myeloma | Large-cell Lymphoma
Changchun GeneScience Pharmaceutical Co., Ltd.

Not yet recruiting

Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.

Breast Cancer Subjects

China
Opna Bio LLC

Not yet recruiting

Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma

Refractory Multiple Myeloma | Relapsed Multiple Myeloma

United States
Shenzhen Geno-Immune Medical Institute
The No.2 Clinical Hospital of the Ministry of Health

Recruiting

Engineered Dendritic Cell Vaccines for Multiple Myeloma

Multiple Myeloma or Plasmacytoma

China, Russian Federation
Shenzhen Geno-Immune Medical Institute
The No.2 Clinical Hospital of the Ministry of Health

Recruiting

Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma

Multiple Myeloma | Plasmacytoma

China, Russian Federation
Janssen Research & Development, LLC

Recruiting

A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-10)

Relapsed or Refractory Multiple Myeloma

Korea, Republic of, United States, Australia
Ontario Clinical Oncology Group (OCOG)
Pfizer

Not yet recruiting

Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma (EMBRACE)

Refractory Multiple Myeloma

Canada
Nantes University Hospital

Not yet recruiting

Evaluation of a Range of Dermo-cosmetic Products to Treat Skin and Nail Toxicity Linked to Bispecific Anti-GPRC5D Bispecific Antibodies in Multiple Myeloma Patients". Myeloma". Descriptive Pilot Study (DELICATESSE)

Myeloma Multiple
Kite, A Gilead Company
Arcellx, Inc.

Not yet recruiting

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma (iMMagine-3)

Multiple Myeloma
Jules Bordet Institute
RayzeBio, Inc.

Not yet recruiting

A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors (AcTRESS)

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory | Multiple Myeloma Progression

Belgium
The First Affiliated Hospital of Soochow University

Not yet recruiting

Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

Multiple Myeloma | Newly Diagnosed | MRD | High Risk
University Hospital, Angers

Not yet recruiting

Impact of an Early Warning System on the Prognosis of Patients With Hematological Malignancies Receiving Intensive Chemotherapy With or Without Hematopoietic Cell Transplantation. (ALHERT)

Lymphoma | Leukemia | Multiple Myeloma

France
Shanghai Changzheng Hospital
CARsgen Therapeutics Co., Ltd.

Recruiting

Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma

Multiple Myeloma

China
Celgene
Bristol-Myers Squibb

Recruiting

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)

Multiple Myeloma

Austria, United States, Spain, Australia, Japan, France, Israel, Italy, Canada, Greece, Belgium, Norway, Romania, Czechia, Denmark, Germany, Korea, Republic of, United Kingdom, Poland
Sidney Kimmel Comprehensive Cancer Center at Johns...
Janssen Research & Development, LLC

Not yet recruiting

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

Lymphoma | Multiple Myeloma | Hodgkin Lymphoma | Myelofibrosis | Non Hodgkin Lymphoma | Chronic Myeloid Leukemia | Hematologic Malignancy | Aplastic Anemia | Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML) | Bone Marrow Transplant Rejection | Acute Lymphoblastic Leukemia (ALL), Adult
Peking University First Hospital

Recruiting

PET Imaging Study of 68Ga-NB381 in Multiple Myeloma

Multiple Myeloma

China
Cullinan Therapeutics Inc.

Not yet recruiting

A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma
Changzhou No.2 People's Hospital

Not yet recruiting

An Clinical Study of NKG2D-CAR-NK Cells for the Treatment of Refractory Recurrent Multiple Myeloma

Multiple Myeloma

China
Dickran Kazandjian, MD
Regeneron Pharmaceuticals

Not yet recruiting

IMMUNOPLANT for Newly Diagnosed Multiple Myeloma (IMMUNOPLANT)

Multiple Myeloma

United States
Jiangsu Simcere Pharmaceutical Co., Ltd.
Shanghai Xianxiang Medical Technology Co., Ltd.

Recruiting

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

China
Peking University People's Hospital

Not yet recruiting

A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma.

Relapsed/Refractory Multiple Myeloma

China
Wuhan Union Hospital, China

Not yet recruiting

Study of SYS6020 in BCMA-positive Multiple Myeloma

Multiple Myeloma
Bristol-Myers Squibb

Recruiting

Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Secondary Malignancy

Multiple Myeloma | Non-Hodgkin Lymphoma | Chronic Lymphocytic Leukaemia

Belgium
Sanofi

Not yet recruiting

A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (SubQSA)

Plasma Cell Myeloma Refractory
Nantes University Hospital
Janssen Pharmaceutica

Not yet recruiting

Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma (IFm2022-01)

Multiple Myeloma

France
Jack Khouri

Not yet recruiting

Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM

Multiple Myeloma | Refractory Multiple Myeloma | Cytokine Release Syndrome | Immune Effector Cell Associated Neurotoxicity Syndrome

United States
Adriana Rossi

Not yet recruiting

ON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

Relapsed and/or Refractory Multiple Myeloma

United States
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Early Assessment of Cardiac Function After Treatment With CAR-T Cells (Cardio CAR-T)

Lymphoma, B-Cell | Multiple Myeloma | Acute Lymphoblastic Leukemia | Hematologic Malignancy | Car T- Cell

France
Thomas Martin, MD
Bristol-Myers Squibb; Janssen Research & Development, LLC

Not yet recruiting

Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Multiple Myeloma | Refractory Multiple Myeloma | Relapsed Multiple Myeloma

United States
UNC Lineberger Comprehensive Cancer Center

Not yet recruiting

Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation

Multiple Myeloma | Newly Diagnosed Multiple Myeloma | Autologous Stem Cell Transplantation

United States
Washington University School of Medicine
National Cancer Institute (NCI); The Foundation for Barnes-Jewish Hospital

Recruiting

Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)

Multiple Myeloma | Rectal Cancer | Cholangiocarcinoma | Colon Cancer

United States
Icahn School of Medicine at Mount Sinai
National Cancer Institute (NCI)

Not yet recruiting

Precision Medicine Study

Multiple Myeloma

United States
CARsgen Therapeutics Co., Ltd.

Not yet recruiting

Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL

Multiple Myeloma | Primary Plasma Cell Leukemia
Emory University
National Cancer Institute (NCI); National Center for Complementary and Integrative...

Recruiting

Chaplain-Delivered Compassion Meditation to Improve Spiritual Care of Patients Receiving Stem Cell Transplantation

Lymphoma | Multiple Myeloma

United States
Senti Biosciences

Recruiting

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

AML/MDS | CD33 Expressing Hematological Malignancies | FLT3 Expressing Hematological Malignancies

United States, Australia
Jinling Hospital, China

Recruiting

Study on the Efficacy and Safety of Low-dose CTX as Maintenance Therapy for MM Unsuitable for Transplantation

Newly Diagnosed Multiple Myeloma

China
The Christie NHS Foundation Trust
CellCentric Ltd.

Not yet recruiting

PatIent exPeRiences and prEFerence of trEatment foR Multiple Myeloma (iPREFER)

Multiple Myeloma

United Kingdom
Leuko Labs, Inc.

Not yet recruiting

Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia (PC002)

Multiple Myeloma | Diffuse Large B Cell Lymphoma
RenJi Hospital
Shanghai JMT-Bio Inc.

Not yet recruiting

Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease

Multiple Myeloma | Bone Diseases
Cartesian Therapeutics

Recruiting

Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma (DC15-MM-01)

Refractory Multiple Myeloma | Relapsed Multiple Myeloma

United States
Institute of Hematology & Blood Diseases Hospital...

Recruiting

Detecting Minimal Residual Diseases (MRD) and Monitoring Clonal Evolution Using Ultrasensitive Chromosomal Aberrations Detection (UCAD) in Multiple Myeloma

Multiple Myeloma
Guangdong Second Provincial General Hospital

Not yet recruiting

To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

China
Juno Therapeutics, Inc., a Bristol-Myers Squibb...

Recruiting

Study of BMS-986393 a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)

Multiple Myeloma

United States, Canada
UNC Lineberger Comprehensive Cancer Center

Not yet recruiting

DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics (DISCOVERY)

Lymphoma | Leukemia | Multiple Myeloma | Hematologic Malignancies | Blood Cancers

United States
Biocad

Recruiting

A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple Myeloma (DARVIVA)

Multiple Myeloma

Russian Federation

Search clinical trials for: Smoldering Multiple Myeloma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Israel

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations